SavedAdd your journal

Journals / ANKEM Dergisi / 2008 / Cilt: 22 - Sayı: 2

The in-vitro activity of tigecycline on ESBL producing Escherichia coli and Klebsiella pneumoniae strains

GSBL pozitif Escherichia coli ve Klebsiella pneumoniae suşlarında tigesiklinin in-vitro etkinliği

İlkay KARAOĞLAN
Yasemin ZER
Mustafa NAMIDURU
Pages
69–71
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tigecyline proved to be an effective antimicrobial against these strains

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In-vitro activity of tigecyline was investigated against extended-spectrum beta-lactamase positive Escherichia coli and Klebsiella pneumoniae strains isolated from patients in the intensive care unit.
📊
Key Findings & Data:In-vitro activity of tigecyline was investigated against extended-spectrum beta-lactamase positive Escherichia coli and Klebsiella pneumoniae strains isolated from patients in the intensive care unit.
💡
Conclusion & Impact:Tigecyline proved to be an effective antimicrobial against these strains
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kültür ortamı · Escherichia coli · In vitro

Abstract

In-vitro activity of tigecyline was investigated against extended-spectrum beta-lactamase positive Escherichia coli and Klebsiella pneumoniae strains isolated from patients in the intensive care unit. Tigecyline proved to be an effective antimicrobial against these strains

Özet

Yoğun bakım ünitesindeki hastalara ait örneklerden izole edilen genişlemiş spektrumlu beta-laktamaz pozitif Escherichia coli ve Klebsiella pneumoniae suşlarında tigesiklinin in-vitro etkinliği araştırılmıştır. Tigesiklinin bu suşlara etkili bir antibiyotik olduğu sonucuna varılmıştır

🔖

Cite This Article

KARAOĞLAN, İ., ZER, Y., NAMIDURU, M. (2008). The in-vitro activity of tigecycline on ESBL producing Escherichia coli and Klebsiella pneumoniae strains. ANKEM Dergisi, Cilt: 22 - Sayı: 2, 69–71. https://ajindex.com/articles/190300

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Bauer G, Berens C, Projan SJ, Hillen W: Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drugdirected Fe2+ cleavage of 16S rRNA, J Antimicrob Chemother 2004;53(4):592-9
  2. Bouchillon SK, Hoban DJ, Johnson BM et al: In vitro activity of tigecycline against 3989 Gram negative and gram positive clinical isolates from the United States. Tigecyline Evaluation and Surveillance Trial (TEST program; 2004), Diagn Microbiol Infect Dis 2005;52(3):173-9
  3. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN: Activity of tigecyline tested against a global collection of Enterobacteriaceae, including tetracycline resistant isolates, Diagn Microbiol Infect Dis 2005;52(3):209-13
  4. Kaya I, Göker G, Bal Kayacan Ç, Gürler N: Yoğun bakım isolatı Gram negatif bakterilerde tigesiklin duyarlılığı, ANKEM Derg 2007;21(3):142-5
  5. Nathwani D: Tigecyline: Clinical evidence and formulary positioning, Int J Antimicrob Agents 2005;25(3):185-92
  6. Petersen PJ, Jocobus NV, Weiss WJ, Sum PE, Testa RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butglycylamido derivative of minocyline (GAR-936), Antimicrob Agents Chemother 1999;43(4):738-44
  7. Wheyt Pharmaceuticals Inc.: Tygacil Product Insert, Philadelphia (PA)
  8. Zhanel GG, Homenuik K, Nichol K et al: The glycylcyclines, a comparative review with tetracylines, Drugs 2004;64(1):63-88.